BioRestorative Therapies Inc

Latest Report Overview

BioRestorative Therapies Inc (BRTX) reported For the quarterly period ended March 31, 2026 (Issuer fiscal Q1 FY2026) revenue of $23.2 thousand with diluted EPS of $-2.43 and net income of -$2.2 million. Operating margin was -14593.5%, and free cash flow was -$3.8 million for the period. During the quarter, management prioritized operational execution on the BRTX-100 clinical program for lumbar disc desiccation. Cash burn remained prominent, with operating cash outflows reaching $3.81 million, reflecting active patient follow-up and clinical trial trial activities. The company maintains a debt-free balance sheet but faces critical near-term capital requirements to sustain operations and clinical trials. Management continues to evaluate various financing alternatives and strategic partnerships to secure necessary runway.

Key Takeaways for BioRestorative Therapies Inc

• BioRestorative Therapies reported Q1 2026 revenue of $23,200, down 7.2% year-over-year, reflecting its pre-commercial clinical-stage status.
• Q1 2026 net loss reached $2,154,400, or -$2.43 per diluted share, driven by research and development expenses of $1,926,300.
• Cash and cash equivalents declined to $3,112,700 as of March 31, 2026, driven by quarterly operating cash burn of $3,807,800.
• The balance sheet carries zero long-term debt, providing a clean capital structure but heightening reliance on equity dilution.
• Clinical execution remains concentrated on the BRTX-100 program for chronic lumbar disc disease as the primary value driver.

What Does BioRestorative Therapies Inc Do?

BioRestorative Therapies, Inc. is a clinical-stage biotechnology company focused on the invention and development of therapeutic products utilizing stem cell technologies and cell-based treatments. The company's primary proprietary programs include BRTX-100, an autologous cultured mesenchymal stem cell procedure for treating discogenic lumbar back pain, and a metabolic program leveraging brown adipose tissue for metabolic disorders such as obesity and type 2 diabetes. Operating within the healthcare and biotechnology sectors, the company targets patients suffering from debilitating chronic conditions where standard medical interventions have proven insufficient. The enterprise operates with a lean structure, dedicating its resources almost entirely to scientific research, intellectual property prosecution, and clinical trial execution.

Growth Drivers for BioRestorative Therapies Inc

• Advancement of the BRTX-100 clinical program for lumbar disc desiccation through active trial enrollment and patient follow-up.